poisar

Stocks · News reference

Valneva's Chikungunya Vaccine Shows Durable Antibody Persistence

Fiscal.ai

Valneva reported new data indicating that its chikungunya vaccine maintains durable antibody persistence across all age groups.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncValneva Se

    Valneva annonce un taux de séroréponse de 94% cinq ans après une dose unique du vaccin contre le chikungunya IXCHIQ®

    Valneva reported positive long-term antibody persistence data for its chikungunya vaccine IXCHIQ®, with 94% of participants maintaining neutralizing antibody levels five years after a single dose. The persistence was comparable across age groups (18-64 years and 65+ years), supporting the vaccine's differentiated profile for a disease with unpredictable epidemic outbreaks. The company continues to generate real-world evidence through post-commercialization studies, including a pilot vaccination campaign in Brazil that vaccinated approximately 80,000 adults.

  2. BenzingaBenzinga Insights

    Full Transcript: Valneva Q2 2026 Earnings Call

    Valneva (NASDAQ:VALN) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and